查詢結果分析
相關文獻
- 慢性淋巴性白血病藥物治療進展
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 豬生殖與呼吸綜合症病毒「gp5重組蛋白」的表現與單株抗體之製備
- Utilization of Monoclonal and Polyclonal Antibodies to Monitor the Protecting and Challenging Strains of Zucchini Yellow Mosaic Virus in Cross Protection
- 單株抗體製備
- Investigations of Breast Masses with Technetium-99m Labeled Anti-mucin Antibody and Technetium-99m-MIBI
- ELISA, Western Blotting, Immunocytolocalization and Immunoaffinity Column for Naturally Occuring Bioactive Compounds Using Monoclonal Antibodies
- 牛乳蛋白單株抗體之製備
- Trastuzumab(Herceptin[feb9])--第一個用於治療癌症的單株抗體
- 利用單株抗體建立犬血清皮質醇之直接式酵素免疫分析法
頁籤選單縮合
題 名 | 慢性淋巴性白血病藥物治療進展=Latest Drug Developments in Chronic Lymphocytic Leukemia |
---|---|
作 者 | 周心怡; 鄭吉元; 陳琦華; | 書刊名 | 藥學雜誌 |
卷 期 | 33:1=130 2017.03[民106.03] |
頁 次 | 頁63-68 |
分類號 | 418.29 |
關鍵詞 | 慢性淋巴性白血病; 單株抗體; B細胞受體通路抑制劑; Chronic lymphocytic leukemia; |
語 文 | 中文(Chinese) |
中文摘要 | 慢性淋巴性白血病 (chronic lymphocytic leukemia;CLL) 是一種淋巴細胞增殖性疾 病,好發於老年人,在臺灣的發生率呈現逐年增高的趨勢。CLL 以藥物治療為主, 包括化療藥物 (烷化劑、嘌呤類似物、bendamustine)、單株抗體、B細胞受體通路抑 制劑,其中新一代單株抗體 ofatumumab、obinutuzumab、alemtuzumab 與B細胞受體 通路抑制劑 ibrutinib、idelalisib 是 CLL 治療的一大進展,CLL 治療未來的趨勢將會由 這些新穎藥物取代傳統的化療藥物。 |
英文摘要 | Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease that occurs mainly in the elderly patients. The incidence of CLL has been reported an increasing trend in Taiwan. CLL treatment regimens incorporate chemotherapies (alkylating agents, purine analogs and bendamustine), monoclonal antibodies and B-cell receptor pathway inhibitors. Recent advances in the treatment of CLL from new generation of monoclonal antibodies (eg: ofatumumab, obinutuzumab, alemtuzumab ) to B cell receptor pathway inhibitors (eg: ibrutinib and idelalisib). New CLL drugs could replace chemotherapy in the near future. |
本系統中英文摘要資訊取自各篇刊載內容。